Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia
Jun Qin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anandan Palani, Ashwin U. Rao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaohong Zhu, Constance Farley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sylvia J. Degrado(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dong Xiao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ying Huang(Guangdong Institute for Drug Control), Yunsheng Hsieh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ganfeng Wang, Xianhai Huang, Fangbiao Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scott Greenfeder, Zhidan Liu(Shandong University), Robert Aslanian(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hongtao Zhang(Chinese Academy of Sciences), Xiao Chen(Zhejiang Provincial People's Hospital), Qiu Li(Qingdao Agricultural University), John A. Cook, Madhu Chintala(Johnson & Johnson (United States)), Stan Kurowski(Merck & Co., Inc., Rahway, NJ, USA (United States)), Margaret van Heek, Boonlert Cheewatrakoolpong(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 23
Related Papers
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
|Journal of Pharmacology and Experimental Therapeutics|2015|336